![ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications](https://cdn.cancerletter.com/media/2024/07/26150602/50-30-4x3-1.jpg)
![ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications](https://cdn.cancerletter.com/media/2024/07/26150602/50-30-4x3-1.jpg)
Cover Story
Regulatory News
By Jacquelyn Cobb and Paul Goldberg
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
Trending Stories
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- Cancer Moonshot contributes additional $100M to reduce cancer burden in Africa
- A view from the BMT unit on the day a Russian cruise missile hit Kyiv’s Ohmatdyt hospital
- Proposed rule by CMS would expand access to cancer treatment at tribal facilities